Literature DB >> 22531864

Glucose intolerance and primary hyperparathyroidism: an unresolved relationship.

Mishaela R Rubin, Shonni J Silverberg.   

Abstract

Primary hyperparathyroidism (PHPT) can be characterized as either symptomatic or asymptomatic, or, most recently, as normocalcemic. In the current issue of the journal, Cakir et al. report that insulin resistance and glucose intolerance is not an aspect of normocalcemic PHPT. However, both the current study as well as the literature are compromised by the lack of appropriate classification of normocalcemic PHPT subjects. Rigorously characterized cohorts are necessary to determine whether glucose intolerance is in fact present in normocalcemic PHPT.

Entities:  

Mesh:

Year:  2012        PMID: 22531864     DOI: 10.1007/s12020-012-9674-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  16 in total

1.  Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism.

Authors:  Semra Ayturk; Alptekin Gursoy; Neslihan Bascil Tutuncu; Derun Taner Ertugrul; Nilgun Guvener Demirag
Journal:  J Clin Endocrinol Metab       Date:  2006-08-08       Impact factor: 5.958

2.  Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening.

Authors:  Emil Hagström; Ewa Lundgren; Jonas Rastad; Per Hellman
Journal:  Eur J Endocrinol       Date:  2006-07       Impact factor: 6.664

3.  Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity.

Authors:  Elizabeth Grethen; Kathleen M Hill; RoseMarie Jones; Brenda M Cacucci; Christine E Gupta; Anthony Acton; Robert V Considine; Munro Peacock
Journal:  J Clin Endocrinol Metab       Date:  2012-02-22       Impact factor: 5.958

4.  Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism.

Authors:  Karen M Tordjman; Marianna Yaron; Elena Izkhakov; Etty Osher; Galina Shenkerman; Yonit Marcus-Perlman; Naftali Stern
Journal:  Eur J Endocrinol       Date:  2010-05       Impact factor: 6.664

5.  Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism.

Authors:  Ilkay Cakir; Kursad Unluhizarci; Fatih Tanriverdi; Gulsah Elbuken; Zuleyha Karaca; Fahrettin Kelestimur
Journal:  Endocrine       Date:  2012-02-12       Impact factor: 3.633

6.  Glucose tolerance and insulin secretion in patients with parathyroid disorders. Effect of serum calcium on insulin release.

Authors:  K Yasuda; Y Hurukawa; M Okuyama; M Kikuchi; K Yoshinaga
Journal:  N Engl J Med       Date:  1975-03-06       Impact factor: 91.245

7.  Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism.

Authors:  S Kumar; A O Olukoga; C Gordon; E B Mawer; M France; J P Hosker; M Davies; A J Boulton
Journal:  Clin Endocrinol (Oxf)       Date:  1994-01       Impact factor: 3.478

8.  Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism.

Authors:  Jens Bollerslev; Thord Rosen; Charlotte L Mollerup; Jörgen Nordenström; Marek Baranowski; Celina Franco; Ylva Pernow; Gunhild A Isaksen; Kristin Godang; Thor Ueland; Svante Jansson
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

9.  Diabetes mellitus, glucose tolerance and insulin response to glucose in patients with primary hyperparathyroidism before and after parathyroidectomy.

Authors:  S Ljunghall; M Palmér; G Akerström; L Wide
Journal:  Eur J Clin Invest       Date:  1983-10       Impact factor: 4.686

10.  Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype.

Authors:  H Lowe; D J McMahon; M R Rubin; J P Bilezikian; S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2007-05-29       Impact factor: 5.958

View more
  6 in total

1.  Insulin sensitivity in normocalcaemic primary hyperparathyroidism.

Authors:  F Tassone; M Maccario; L Gianotti; C Baffoni; M Pellegrino; S Cassibba; F Cesario; G Magro; G Borretta
Journal:  Endocrine       Date:  2013-09-25       Impact factor: 3.633

2.  Emerging data on cardiovascular risk in primary hyperparathyroidism.

Authors:  Jessica Pepe; Sara Piemonte; Cristiana Cipriani; Mirella Cilli; Salvatore Minisola
Journal:  Endocrine       Date:  2014-09-10       Impact factor: 3.633

3.  Investigation of glucose intolerance in patients with normocalcemic primary hyperparathyroidism: 4-year follow-up.

Authors:  Halit Diri; Kursad Unluhizarci; Fahrettin Kelestimur
Journal:  Endocrine       Date:  2014-04-11       Impact factor: 3.633

4.  Evaluation of left ventricle functions by tissue Doppler, strain, and strain rate echocardiography in patients with primary hyperparathyroidism.

Authors:  Didem Ozdemir; Gulhan Yuksel Kalkan; Nihal Akar Bayram; Eda Demir Onal; Reyhan Ersoy; Engin Bozkurt; Bekir Cakir
Journal:  Endocrine       Date:  2014-03-28       Impact factor: 3.633

5.  Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms.

Authors:  M Procopio; M Barale; S Bertaina; S Sigrist; R Mazzetti; M Loiacono; G Mengozzi; E Ghigo; M Maccario
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

6.  Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study.

Authors:  Sophie Norenstedt; Ylva Pernow; Kerstin Brismar; Maria Sääf; Ayla Ekip; Fredrik Granath; Jan Zedenius; Inga-Lena Nilsson
Journal:  Eur J Endocrinol       Date:  2013-10-21       Impact factor: 6.664

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.